DOI: 10.36347/sjmcr.2018.v06i12.019

Pages: 1068-1070

Ig D myeloma is the rarest subtype of multiple myeloma and accounts for 2 % of all symptomatic myelomas. Majority of patients who present with IgD myeloma has lambda light chain and present with advanced disease stages and are associated with somatic hyper-mutation of IgV regions. The survival of patients with IgD MM is shorter in comparison to those with immunoglobulin G (IgG) myeloma but the outcomes are improving with the use of novel. Here we present the case of a 47 year old male with Ig D myeloma who presented with cauda equina syndrome. The patient was treated with bortezomib lenalidomide and dexamethasone chemotherapy.